Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.31 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.31 |
| ▸ | PLG | P00747 | 1/20 | 0.30 |
| ▸ | PLAU | P00749 | 1/20 | 0.30 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.30 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.30 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.30 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.30 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.30 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.30 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20375331 | 1.00 | GLP1R (0.42) | GLP1RPOLBALDH1A1MAPTGRIN1 | |
| SCHEMBL21287423 | 1.00 | GLP1R (0.42) | GLP1RPOLBALDH1A1MAPTGRIN1 | |
| SCHEMBL20800976 | 0.93 | GLP1R (0.41) | GLP1RPOLBALDH1A1MAPTKMT2A | |
| SCHEMBL20800932 | 0.93 | GLP1R (0.43) | GLP1RPOLBALDH1A1MAPTGRIN1 | |
| SCHEMBL24135562 | 0.93 | GLP1R (0.39) | GLP1RPOLB | |
| SCHEMBL25656627 | 0.93 | GLP1R (0.37) | GLP1RPOLB | |
| SCHEMBL24697086 | 0.92 | GLP1R (0.37) | GLP1RPOLB | |
| SCHEMBL24479569 | 0.92 | GLP1R (0.43) | GLP1RPOLBALDH1A1MAPTGRIN1 | |
| SCHEMBL22566689 | 0.92 | GLP1R (0.41) | GLP1RPOLBALDH1A1MAPTKMT2A | |
| SCHEMBL18715404 | 0.92 | GLP1R (0.43) | GLP1RPOLBALDH1A1MAPTGRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220170015-A1 | ALPHA-1 ANTITRYPSIN (AAT) RNAI AGENTS, COMPOSITIONS INCLUDING AAT RNAI AGENTS, AND METHODS OF USE | Arrowhead Pharmaceuticals, Inc. (US) | 2022-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220170015-A1 | ALPHA-1 ANTITRYPSIN (AAT) RNAI AGENTS, COMPOSITIONS INCLUDING AAT RNAI AGENTS, AND METHODS OF USE | SERPINA2, SERPINC1, SERPINA3 | GLP1R 4004/4885POLB 2045/4885ALDH1A1 1280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.